Breast cancer specialist Hope S. Rugo, MD, FASCO, an advisory board member for The Center for Biosimilars®, has been at the forefront of groundbreaking oncology advancements.
Center for Biosimilars® Advisory Board member Hope S. Rugo, MD, FASCO, has been named among the winners of this year’s OncLive® Giants of Cancer Care® awards. Rugo, an investigator and breast cancer practitioner with the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), was named the recipient of the Education award.
She is among 15-world renowned leaders in oncology who will be officially honored at the Giants of Cancer Care® virtual celebration on November 5. A video of the November ceremony will be available on demand after the event by visiting giantsofcancercare.com. The many award categories include Cancer Diagnostics, Lymphoma, Community Outreach, and Translational Science.
Rugo has been a noted clinical research leader and lecturer at worldwide conferences. At UCSF, she runs the Breast Forum, which brings together patients, families, and caregivers for helpful information and discussion about managing breast cancer.
She had important investigational roles in the EMBRACA and ABRAZO studies, which evaluated the efficacy of talazoparib (Talzenna), a poly(ADP-ribose) polymerase that prevents damaged cancer cells from repairing themselves, thereby impairing tumor growth. This important drug was approved by the FDA in 2018 for patients with HER2-negative locally advanced or metastatic breast cancer with germline BRCA mutations.
Rugo was also involved in evaluation of atezolizumab (Tecentriq) in the IMpassion130 trial, which led to the FDA’s March 2019 approval of the immunotherapeutic agent in combination with nab-paclitaxel (Abraxane) for PD-L1–positive unresectable locally advanced or metastatic triple-negative breast cancer. Tecentriq prevents cancer cells from disabling the immune system and preventing attacks on cancer cells.
Rugo has also contributed to the approvals of scalp-cooling technology to reduce chemotherapy-induced hair loss and a steroid mouthwash to relieve oral inflammation resulting from targeted therapy.
At Helen Diller, Rugo is director of the Breast Oncology Clinical Trials Program and a clinical professor of medicine. She holds a postdoctoral award from the AP Giannini Foundation (1990) and has been honored by Friends of the Breast Care Center (2006) and Cancer Care National Organization (2010).
Click here for a video of Rugo talking about the need for education to improve biosimilar uptake.
Other 2020 Giants of Cancer Care® to be honored at the November event are listed below:
Samsung Bioepis Report Showcases Adalimumab Biosimilar Growth in Market Share
October 11th 2024Adalimumab biosimilars have seen a significant increase in market share, from 2% in early 2024 to 22%, as payers and pharmacy benefit managers begin to prioritize these biosimilars over the reference product, Humira.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Duke Publishes Recommendations for Developing CGT Biosimilars
October 9th 2024Transformative cell and gene therapies (CGT) offer promising treatments for serious conditions, but high costs and complex biologics limit competition, requiring policies that support the development of biosimilars to enhance affordability and patient access.
Biosimilars Oncology Roundup for June 2024—Podcast Edition
July 7th 2024On this episode of Not So Different, we review biosimilar news coming out of June, with clinical trial results from conferences and a study showcasing how to overcome economic and noneconomic barriers to oncology biosimilars.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.